A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Pediatric Subjects 6 to <12 Years Old With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

Vitiligo is a common, long-lasting disease that happens when the immune system attacks melanocytes (skin cells that produce the skin-coloring pigment melanin) in the skin leading to loss of color. Non-segmental vitiligo (NSV) occurs when patches of color loss appear on both sides of the body, such as both knees or both hands. This study is to evaluate how effective, safe and tolerable upadacitinib is for the treatment of non-segmental vitiligo in pediatric participants ages 6 to 11 years old.
This study will have two periods: Period A and Period B. In Period A, participants are placed in 1 of 2 groups called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will receive placebo. Participants who complete Period A will continue into Period B and remain on blinded treatment.
In Studies 1 and 2: Period A, participants will receive oral tablets (or oral solution) of upadacitinib or placebo once a day for 48 weeks. In Period B,participants who complete Period A will continue into Period B and remain on blinded treatment for 112 weeks. Participants will be followed up for 30 days. This study will enroll approximately 154 pediatric participants at 110 sites worldwide.
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2027-01-28

申办/合作机构

AbbVie, Inc.

NCT07904754

/ Not yet recruiting临床2期

A Phase 2b, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints, causing pain, swelling, stiffness, and loss of function. Synovial fibroblasts play a key role in RA pathogenesis, with treatment-refractory patients demonstrating increased numbers of these cells. The goal of this study is to evaluate the safety and effectiveness of ABBV-2294 (a combination of ABBV-722 and upadacitinib) compared to each drug alone in treating moderately to severely active RA. The platform study will measure improvements in disease activity using the American College of Rheumatology (ACR) criteria, changes in disease activity scores, and quality of life measures.
ABBV-2294 is an investigational combination drug being developed for the treatment of moderately to severely active rheumatoid arthritis. This is a Phase 2b, randomized, double-blind platform study. In sub-study 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment consisting of either ABBV-722 alone, upadacitinib alone, or various doses of ABBV-722 combined with upadacitinib. Adult participants with a diagnosis of moderately to severely active rheumatoid arthritis who have failed at least 1 prior biologic disease-modifying antirheumatic drug (bDMARD) will be enrolled. Around 250 participants will be enrolled in the study at multiple sites worldwide.
Participants will receive oral tablet doses of ABBV-2294 (combination of ABBV-722 and upadacitinib), ABBV-722 alone, or upadacitinib alone. The study comprises a 24-week Double-Blind Phase (Period 1) followed by an optional 52-week Blinded Long Term Extension Phase (Period 2), for a total treatment duration of up to 76 weeks. After completing treatment, participants will have a 30-day Follow-Up Period.
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic, including screening, baseline, and scheduled visits through Week 76, followed by a follow-up visit. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.

开始日期2026-12-07

申办/合作机构

AbbVie, Inc.

NCT07700446

/ Not yet recruiting临床4期

A Single Arm, Multicenter Open-Label Interventional to Evaluate the Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose

ReCOUP is a multicenter clinical study designed to evaluate the efficacy of upadacitinib (Rinvoq®) in patients with ulcerative colitis whose disease has become active again despite maintenance treatment with upadacitinib 30 mg.
This study involves adult patients aged 18 to 64 years with active ulcerative colitis, who are being treated with upadacitinib and are not participating in another interventional clinical trial.
Participation in this study will depend on the patients' response to treatment during the 52-week maintenance period.
Several follow-up visits will be scheduled throughout the study according to a timetable defined by the protocol, and additional visits may be arranged if necessary depending on patients' health status.

开始日期2026-11-15

申办/合作机构

Getaid

100 项与乌帕替尼相关的临床结果

登录后查看更多信息

100 项与乌帕替尼相关的转化医学

登录后查看更多信息

100 项与乌帕替尼相关的专利（医药）

登录后查看更多信息

2,055

项与乌帕替尼相关的文献（医药）

2027-03-01·BIOMATERIALS

Upadacitinib and shikonin co-loaded nanodrug for rheumatoid arthritis therapy via attenuating inflammation and protecting cartilage

Article

作者: Cai, Xiong ; Liu, Bin ; Yan, Ping ; Tang, Yuanyuan ; Liu, Liang ; Liu, Longji ; Lin, Ye ; Li, Mengyan ; Yang, Mengxue

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, excessive oxidative stress, and progressive joint destruction. Although upadacitinib (UP) monotherapy exhibits robust anti-inflammatory efficacy, its systemic administration is limited by a narrow target profile and hepatotoxicity. To address these challenges, we rationally designed a biomimetic nanodrug (HA-M@SHK-Fe@BSA-UP NPs) co-delivering UP with shikonin (SHK), a natural naphthoquinone with antioxidant activity and hepatoprotective effects. This nanoplatform self-assembled via iron-mediated metal-phenolic coordination, using bovine serum albumin (BSA) as a bridge, with a dual-surface modification of erythrocyte/macrophage hybrid membrane (M) and hyaluronic acid (HA). This architecture enabled prolonged circulation and pH-responsive drug release. In vitro, the nanodrug exhibited efficient reactive oxygen species (ROS) scavenging and targeted cellular uptake. Mechanistically, the nanodrug acted on macrophages and primary rat knee-joint chondrocytes (PRKCs) in parallel. It effectively drove M1-to-M2 polarization at least in part through the JAK1/STAT3/PKM2 axis and directly restored the function of PRKCs to suppress matrix degradation. In vivo, Ce6-based fluorescence imaging showed that the nanodrug accumulated 4.55-fold more in arthritic joints than free Ce6. Moreover, this nanodrug significantly suppressed inflammation at a low dosage and promoted cartilage and bone repair in AIA and CIA rat models, while showing reduced signs of liver injury. In summary, this self-assembled nanodrug offers a promising strategy for inflammatory disease treatment.

2027-03-01·JOINT BONE SPINE

Infection risk associated with steroid-sparing therapies in GCA, PMR, and ANCA-associated vasculitis: A systematic review

Article

作者: Sudireddy, Divya ; Neogi, Tuhina ; LaValley, Michael ; Leung, Brent ; Liew, Jean W ; Felson, David ; Flynn, David

OBJECTIVE:

Giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and ANCA-associated vasculitis (AAV) often require prolonged glucocorticoid therapy. Steroid-sparing biologic and small molecule therapies reduce glucocorticoid exposure, but may increase infection risk, particularly in older adults. We evaluated infection risk associated with these therapies with concomitant glucocorticoid treatment, versus glucocorticoid treatment alone, in vasculitis/PMR clinical trials.

METHODS:

We searched PubMed, Embase, Cochrane, and ClinicalTrials.gov using terms related to GCA, PMR, AAV, biologics (tocilizumab, sarilumab), small molecule therapies (upadacitinib, avacopan), glucocorticoids, and infection outcomes. We included randomized controlled trials (RCTs) comparing biologics or small molecules plus glucocorticoid (active intervention) versus glucocorticoid monotherapy (comparator) reporting infection outcomes. We calculated the relative risk (RR) of infection and difference in glucocorticoid dose between the comparator and active intervention groups.

RESULTS:

We included 10 RCTs (1487 patients total, enrolling adults averaged≥50 years): 4 tocilizumab, 3 avacopan, 2 sarilumab, and 1 upadacitinib. When the active intervention had much lower glucocorticoid dosing than the comparator, the RR for infection was either close to 1 or<1. When the active intervention glucocorticoid dose was comparable to the comparator, the RR for infection was>1.

CONCLUSION:

Steroid-sparing therapies reduced glucocorticoid exposure with varying magnitudes but were not consistently associated with lower infection risk. These findings underscore the heightened risk of infection when these novel therapies are used in combination with glucocorticoids when the glucocorticoid dose cannot be adequately tapered, particularly in older adults.

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort

Article

作者: Ulutaş Demirbaş, Gözde ; Esen, Mustafa ; Diremsizoglu, Esin ; Demirbaş, Abdullah

BACKGROUND:

Dose-stratified real-world data for JAK1 inhibitors in AD are limited.

OBJECTIVE:

To compare effectiveness and safety of standard vs high doses of abrocitinib and upadacitinib in routine care.

METHODS:

Multicenter, retrospective cohort study. The primary endpoint was Week-12 achievement of Eczema Area and Severity Index (EASI)-75. Secondary outcomes included patient-reported improvements at Minimal Clinically Important Difference (MCID) thresholds, Minimal Disease Activity (MDA) at Week 36, time-to-EASI-75, and treatment-emergent adverse events(TEAE).

RESULTS:

A total of 124 patients were analyzed (abrocitinib 100 mg, n = 28; abrocitinib 200 mg, n = 32; upadacitinib 15 mg, n = 30; upadacitinib 30 mg, n = 34). At Week 12, EASI-75 was achieved in 20/32 (62.5%) versus 10/28 (35.7%) for abrocitinib (OR 2.94, 95% CI 1.06-8.15; p = 0.036) and in 22/34 (64.7%) versus 14/30 (46.7%) for upadacitinib (OR 2.92, 95% CI 1.16-7.38; p = 0.021), favoring the higher-dose regimens. Itch improvement was more frequent with higher doses. By Week 36, full minimal disease activity was observed in 30.2% of patients receiving abrocitinib 200 mg and 26.7% receiving upadacitinib 30 mg, compared with 18.4% and 20.0% in the lower-dose groups. Kaplan-Meier analysis showed faster responses with high doses (median 12 vs 36 weeks; log-rank p < 0.01). Safety was comparable across groups.

CONCLUSION:

High-dose JAK1 regimens achieve faster, numerically greater disease control without short-term safety tradeoffs, supporting escalation in suboptimal responders.

3,987

项与乌帕替尼相关的新闻（医药）

2026-11-03

·求实药社

同一款药，拆成两笔生意！先声与凌科在算什么账？

11月2日，先声药业与凌科药业签约，拿下泽普昔替尼在成人中重度特应性皮炎及其他皮肤科适应症、中国大陆及港澳台地区的独家商业化权益。这款药四年多前跟先声签过一次，签的是类风湿关节炎和强直性脊柱炎。公告未披露财务安排。一、先看协议的名字一份协议的性质，有时能从标题看出。港交所公告写的是“订立独家推广服务协议”，exclusive promotion services agreement，不是许可，也不是转让。 2022年3月那笔，招股书有载：先声支付1.33亿元前期商业化权益对价，取得这两个适应症的大中华区独家商业化权益；销售收入归凌科，先声负责推广，按销售额与市场份额收取服务费。公告能确认的只有协议名称、适应症范围与地域；付款、服务费与收入归属，一字未提。2022年那笔虽同属商业化合作安排，先声仍支付了1.33亿元前期对价，可见本次未披露金额，不是合作模式本身决定的。凌科今年6月递表的招股书写着，AD商业化“正探索与CSO合作伙伴的潜在合作，且尚未达成任何最终协议”；不到五个月后，协议落地。二、真正被拆开的是什么这里的“按科室卖”，准确说是按治疗领域拆分权益。两个领域的目标医生、治疗决策链条、竞品格局与准入路径都不同。有一层容易被说错：这次不是把两个领域分给两家，而是同一家先声拿走了两块——同一个伙伴，分领域、分次签约。不同治疗领域的市场空间与商业化节奏不同，分开签约，双方可以分别协商权益，也为设置不同的对价与考核留下空间。不过，本次是否独立定价，公开信息并未披露——这是分析，不是公告里的话。这笔合作也与先声持续拓展皮肤科产品组合有关。今年6月1日，它已与普祺医药就普美昔替尼凝胶签订独家推广服务协议，拿到这款外用JAK在内地、香港、澳门的推广权，成人及青少年AD上市申请已获受理；两款产品申报适应症分处轻中度与中重度，有望在渠道、推广与准入上形成协同，但是否共用队伍，公开资料没说。对先声来说，这种模式不必承担早期研发投入，能用现成网络承接临近上市品种；代价是不拥有产品的知识产权，还要担推广与准入风险。对凌科来说，保留产品及研发权益，借先声的网络推进市场拓展；服务费用与收益分配，仍待协议披露。三、药本身泽普昔替尼是凌科自研的口服高选择性JAK1抑制剂，公司将其定位为“第二代”。第二代JAK抑制剂并无统一定义，第一代也不等于泛JAK抑制剂，差别在对JAK1、JAK2、JAK3、TYK2的选择性谱。但体外选择性更高，不等于临床安全性已被证明：严重感染、血栓、主要心血管事件及恶性肿瘤风险不能仅凭体外选择性推断，仍需更长时间、更大规模的数据。机制上，JAK1参与IL-4、IL-13、IL-31等细胞因子信号传导，这些通路参与特应性皮炎的2型炎症与瘙痒。抑制JAK1有望同时改善皮损与瘙痒——这是机制解释，不是已验证的临床结论。关键III期由北京大学人民医院张建中、周城牵头，356例按1:1:1随机至12mg、24mg、安慰剂。双主要终点为第16周达到EASI-75的患者比例，以及达到vIGA-AD 0/1应答的比例；关键次要终点为WI-NRS评分较基线下降至少4分的患者比例。顶线数据显示，两个剂量组的EASI-75应答率较安慰剂分别高出38.1和46.4个百分点，vIGA-AD 0/1应答率分别高出30.3和31.0个百分点，WI-NRS4应答率分别高出31.3和31.0个百分点。差异均具有统计学意义（p值均小于0.0001）；瘙痒改善在第1天即与安慰剂出现统计学差异。这是企业披露的顶线结果，完整数据尚待发表，疗效评价止于第16周。招股书另披露，其全部临床研究已入组逾1600人，其中逾450人完成超过52周的长期研究——但这不是AD III期的长期结果。NDA于4月7日获CDE受理，公司预计2027年下半年获批。顶线数据只回答有无疗效信号；竞争力还要看长期安全性、与现有疗法的比较价值以及上市后的可及性。四、冷静的一面第一，这笔交易现在算不出分量。“其他皮肤科适应症”是覆盖性表述，边界与优先权均未说明。它在皮肤科最明确的基础是AD，白癜风仍处早期；凌科另一款皮肤科资产LNK01004是外用泛JAK，不在这份协议里。“其他”的价值取决于后续开发与获批，不是已落地的销售。第二，证据有边界。III期是安慰剂对照，没有头对头；顶线只公布较安慰剂的差值，各臂绝对应答率未披露。这只说明取得积极信号，不能判断优于已上市药物——不同研究也不能横向比较。第三，赛道不算空白。度普利尤单抗等生物制剂已占住位置，乌帕替尼、阿布昔替尼已在国内上市；国产艾玛昔替尼同属高选择性JAK1抑制剂，AD适应症2025年3月获批，是最直接的参照。第四，凌科目前仍处在商业化落地前的阶段。截至今年3月末，现金及现金等价物1.44亿元，另有5000万元定期存款；一季度经营活动现金流净额为负，当季3864万元收入来自LNK01006海外授权，并非产品销售收入。2025年11月首次递表、2026年6月再次递表；公司尚无已商业化产品，无自有生产设施、拟委托CDMO生产，商业化主要依赖先声的网络。研发与注册申报仍是本分，但省下自建投入，放量也取决于伙伴。结束语这起合作值得记的不是又一起BD，而是一种切法：适应症按治疗领域分，权益分领域安排、分次签约。这种安排在跨国药企中并不陌生；对本土药企，则是一种值得关注的选择，而非已成形的趋势。更值得问的是：这次合作看重的是先声跨领域的推广能力，还是泽普昔替尼在两个领域的商业价值本就可以独立核算？两者未必互斥，但公开信息回答不了。至于药，顶线数据显示其取得积极疗效结果；是否更好，还没有答案。联系我们 I-RNA 2027 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

引进/卖出

2026-11-03

·摩熵医药

再次达成合作！先声药业再获一款JAK1新药

11月2日，先声药业发布公告，宣布与凌科药业（浙江）股份有限公司达成新一轮合作，获得选择性JAK1抑制剂泽普昔替尼在中国大陆及港澳台地区，用于成人中重度特应性皮炎及其他皮肤科适应症的独家商业化权益。截图来源：先声药业企业公告这是双方继2022年3月首次合作后的再次携手。此前，先声药业已获得泽普昔替尼治疗类风湿关节炎、强直性脊柱炎两大适应症的大中华区独家商业化权益。本次合作进一步将商业化布局拓展至皮肤科领域。值得关注的是，泽普昔替尼治疗中重度特应性皮炎的关键性Ⅲ期临床研究已完成，相关新药上市申请（NDA）于2026年4月获国家药监局药品审评中心（CDE）受理。 01 二度合作，商业化权益再扩容泽普昔替尼由凌科药业自主研发，是一款高选择性、口服第二代JAK1抑制剂，正在开发用于类风湿关节炎、特应性皮炎及强直性脊柱炎等炎症和自身免疫性疾病。来源：摩熵医药全球.药物研发数据库（查数据.找摩熵）此次合作是双方2022年首次合作后的进一步扩容。先声药业在原有风湿免疫适应症商业化权益基础上，新增获得泽普昔替尼在特应性皮炎及其他皮肤科适应症的独家商业化权益。摩熵医药数据库显示，目前，JAK3抑制剂SIM-0280也在布局自身免疫性疾病领域，尚处于临床前研究阶段。来源：摩熵医药全球.药物研发数据库（查数据.找摩熵）对于先声药业而言，此次合作有望进一步丰富自身免疫领域产品组合，并利用现有商业化体系推进产品市场开发；对于凌科药业而言，则可以借助先声药业的商业化能力，为产品后续上市及市场推广提供支持。双方此次合作的具体交易金额、里程碑付款及销售分成比例尚未披露。 02 III期临床完成，特应性皮炎上市申请获受理临床数据方面，泽普昔替尼治疗中重度特应性皮炎的Ⅲ期研究共纳入356例患者。结果显示，治疗第16周时，两个剂量组在EASI-75、vIGA-AD 0/1及瘙痒改善等终点上均显著优于安慰剂组。起效时间方面，给药后第1天即可观察到瘙痒改善，第2周开始出现皮损改善。安全性方面，不良事件以轻中度为主，严重不良事件和特别关注不良事件发生率与安慰剂组基本相当，未发现新的安全性信号。来源：摩熵医药全球.药物研发数据库（查数据.找摩熵）除特应性皮炎外，泽普昔替尼治疗类风湿关节炎的Ⅲ期临床研究已完成，针对强直性脊柱炎的Ⅲ期临床开发项目仍在进行中。目前，特应性皮炎领域已有度普利尤单抗等生物制剂，以及乌帕替尼、阿布昔替尼等口服JAK抑制剂。泽普昔替尼未来若顺利获批，仍需面对较为充分的市场竞争，其疗效、安全性及长期用药表现将成为影响市场竞争力的重要因素。从首次合作到权益扩容，先声药业与凌科药业进一步深化泽普昔替尼的商业化合作。随着特应性皮炎适应症进入上市申请审评阶段，这款国产口服JAK1抑制剂的后续进展值得关注。 END 本文为原创文章，转载请留言获取授权注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。点击阅读原文，申请摩熵医药企业版免费试用！

临床3期申请上市临床成功

2026-11-03

·药代动力学

A司也太猛了吧！

艾伯维也太猛了吧！ 10 月30 日，艾伯维发布 2026 年 Q3 财报。财报显示，2026 年前三季度，艾伯维营收 493.96 亿美元，同比增长 10.9 %。按营收规模计算，艾伯维依然稳居全球制药企业行业前五。其中，在 Q3，艾伯维营收 174.04 亿美元，同比增长 10.3%，并已经连续多个季度保持双位数增长。免疫业务依赖「双子星」继续强势增长，肿瘤业务在产品商业化与创新管线方面不断取得进展，神经科学业务正在全力冲刺全球第一「王座」。如果说过去的艾伯维，擅长把单品打造成全球重磅「明星」药物，那么今天的艾伯维，正在把「造星」升级为一套系统工程：以免疫产品矩阵持续发力，以肿瘤、神经科学开拓第二增长曲线，再通过研发、并购、合作，为下一轮产品接力储备资产。前三季度，艾伯维免疫业务实现营收 252.41 亿美元，继续卫冕「免疫之王」。其中，利生奇珠单抗（喜开悦®）实现营收157.64亿美元，同比增长25.6%；乌帕替尼（瑞福®）实现营收 73.50 亿美元，同比增长 23.9%。两款产品分别瞄准 IL-23 通路、JAK 抑制机制，构成艾伯维免疫业务的「双子星」，并通过不断拓宽免疫治疗版图释放增长动能，再次逼近全年营收目标。若全年业绩兑现预期，两款产品有望分别跨越百亿和双百亿美元门槛，实现1（喜开悦）+1（瑞福）>3（百亿）的收官成就！肿瘤与神经科学业务，正在快速成长为艾伯维营收的「新增长极」。2026年前三季度，艾伯维全球肿瘤业务营收达到 49.77 亿美元。本季度肿瘤板块最值得书写的里程碑，是艾可瑞妥单抗（艾可来®）于 10 月末正式供应中国市场，为我国复发或难治性滤泡性淋巴瘤（FL）成人患者开启了双抗治疗新阶段。此前 5 月，艾可瑞妥单抗获批联合利妥昔单抗和来那度胺（R²方案）用于治疗复发或难治性滤泡性淋巴瘤（FL）成人患者，这是艾伯维首个在华获批的双特异性抗体产品，也是艾可瑞妥单抗在中国的首个监管批准。其正式供应，也意味着艾伯维肿瘤业务在中国从「临床研发」迈入「商业化销售」的新阶段。 2026年前三季度，艾伯维全球神经科学业务营收狂飙 21.6% 到 94.92 亿美元。按照这一营收规模，艾伯维与全球神经科学领域的「头把交椅」的差距不足 0.5 亿美元。且按当前增速，艾伯维将有望在年底正式完成反超并登顶。艾伯维已搭建起覆盖抑郁症、偏头痛、精神分裂症、帕金森病、阿尔茨海默病等多适应症的神经科学全球产品矩阵。艾伯维的「造星术」正在从单品成功、「免疫王者」，走向多业务、多阶段的增长接力。纵观近一年的业绩，艾伯维已连续多个季度保持营收双位数增长。对于一家营收规模位居全球前列的跨国药企而言，在如此体量之上持续跑出这一增速，尤显难得，也展现出其在跨国药企竞争中的强劲增长韧性。这份成绩单背后，是免疫「双子星」持续发力、肿瘤业务拓展布局与神经科学加速增长共同勾勒的「造星」路径：从打造明星单品，到培育多领域的明星产品组合，再以研发、并购与合作储备下一棒增长力量，艾伯维正将「造星」转化为持续接力的增长动能！

财报免疫疗法

100 项与乌帕替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10994 D11048	乌帕替尼	L04AF03	DB15091

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
斑秃	欧盟	AbbVie, Inc.	2026-07-29
斑秃	冰岛	AbbVie, Inc.	2026-07-29
斑秃	列支敦士登	AbbVie, Inc.	2026-07-29
斑秃	挪威	AbbVie, Inc.	2026-07-29
非节段型白癜风	欧盟	AbbVie, Inc.	2026-06-29
非节段型白癜风	冰岛	AbbVie, Inc.	2026-06-29
非节段型白癜风	列支敦士登	AbbVie, Inc.	2026-06-29
非节段型白癜风	挪威	AbbVie, Inc.	2026-06-29
巨细胞动脉炎	欧盟	AbbVie Deutschland GmbH & Co. KG	2025-04-08
巨细胞动脉炎	冰岛	AbbVie Deutschland GmbH & Co. KG	2025-04-08
巨细胞动脉炎	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2025-04-08
巨细胞动脉炎	挪威	AbbVie Deutschland GmbH & Co. KG	2025-04-08
多关节型幼年特发性关节炎	美国	AbbVie, Inc.	2024-04-26
活动性中度克罗恩病	欧盟	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性中度克罗恩病	冰岛	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性中度克罗恩病	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性中度克罗恩病	挪威	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性重度克罗恩病	欧盟	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性重度克罗恩病	冰岛	AbbVie Deutschland GmbH & Co. KG	2023-04-24
活动性重度克罗恩病	列支敦士登	AbbVie Deutschland GmbH & Co. KG	2023-04-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
小儿克罗恩病	临床3期	美国	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	中国	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	日本	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	澳大利亚	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	比利时	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	巴西	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	保加利亚	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	加拿大	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	法国	AbbVie, Inc.	2024-08-08
小儿克罗恩病	临床3期	希腊	AbbVie, Inc.	2024-08-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03738397 (Heads Up, Pubmed \| J Dermatolog Treat)	临床3期	特应性皮炎	385	Dupilumab	顧構蓋淵網遞夢構築網(艱觸鬱窪製遞醖鑰構選) = 鏇鏇鏇夢憲觸製鑰選蓋網範膚糧鹽鹽艱繭顧襯 (衊蓋壓鹹齋願選襯艱齋 )	积极	2026-12-31
				Upadacitinib	顧構蓋淵網遞夢構築網(艱觸鬱窪製遞醖鑰構選) = 選窪憲壓餘醖構壓鑰鹹網範膚糧鹽鹽艱繭顧襯 (衊蓋壓鹹齋願選襯艱齋 )
ACR2026	N/A	类风湿关节炎	27,586	Tofacitinib	壓選憲廠憲齋糧齋衊鑰(網廠獵簾艱願壓鹹構範) = 獵觸網鬱齋選膚齋壓衊淵糧憲窪廠鏇鬱觸鏇窪 (壓鹽蓋築憲範鬱窪觸膚 ) 更多	积极	2026-11-06
				Upadacitinib/Baricitinib	壓選憲廠憲齋糧齋衊鑰(網廠獵簾艱願壓鹹構範) = 夢鏇鏇鏇鏇蓋齋壓範壓淵糧憲窪廠鏇鬱觸鏇窪 (壓鹽蓋築憲範鬱窪觸膚 ) 更多
ACR2026	N/A	银屑病关节炎 \| 类风湿关节炎 herpes zoster \| injury	39,603	Upadacitinib	餘觸醖選廠窪獵遞夢餘(鹹膚醖顧鬱壓蓋簾構窪): HR = 0.84 (95.0% CI, 0.4 ~ 1.74) 更多	积极	2026-11-06
				Tofacitinib
ACR2026	N/A	巨细胞动脉炎	40	Upadacitinib	夢憲繭鏇膚構餘遞夢蓋(簾齋蓋襯壓蓋夢艱築淵) = 夢製築構衊鹽醖艱網願網網糧鹹遞獵餘壓憲鹹 (築範願鹽鑰夢餘築構鹽 ) 更多	积极	2026-11-06
UPHOLD (ACR2026)	N/A	类风湿关节炎	1,494	Upadacitinib (Remission)	艱築鏇網鏇衊廠襯簾襯(鹹廠獵鏇憲窪願簾壓鏇) = 鹽簾壓醖鑰鏇艱襯廠淵願襯鹹願積鹹簾餘顧夢 (鹽壓遞觸選窪鬱網遞壓 ) 更多	积极	2026-11-06
				Upadacitinib (LDA)	艱築鏇網鏇衊廠襯簾襯(鹹廠獵鏇憲窪願簾壓鏇) = 製鹹襯鏇遞壓餘鹽齋衊願襯鹹願積鹹簾餘顧夢 (鹽壓遞觸選窪鬱網遞壓 ) 更多
SELECT-GCA (ACR2026)	临床3期	巨细胞动脉炎	101	Upadacitinib 15 mg	壓願蓋繭鏇夢繭壓糧築(範餘製構鹹鬱衊蓋遞淵) = The increase in mean (SD) levels of CRP from period 2 entry to the first flare was 0.7 (2.6) mg/dL for the UPA15/UPA15 group and 2.2 (2.2) mg/dL for the UPA15/PBO group. 範繭艱範範積糧夢顧齋 (艱繭鏇顧網膚構遞繭衊 ) 更多	积极	2026-11-06
				Placebo
ACR2026	N/A	银屑病关节炎	1,797	Upadacitinib	鹽醖鬱鬱齋齋衊構艱艱(網糧遞獵淵築選築廠膚) = 窪壓獵鏇構構鏇膚窪糧餘選鏇繭鏇膚鏇襯鬱鏇 (壓鹹鏇齋糧蓋繭壓繭餘, -1.50 ~ -0.85) 更多	积极	2026-11-06
				Interleukin-17 inhibitor (IL-17i)	鹽醖鬱鬱齋齋衊構艱艱(網糧遞獵淵築選築廠膚) = 獵憲築壓鹽淵簾淵艱願餘選鏇繭鏇膚鏇襯鬱鏇 (壓鹹鏇齋糧蓋繭壓繭餘, -1.02 ~ -0.6) 更多
ACR2026	N/A	巨细胞动脉炎	63	Upadacitinib	醖鏇鹹繭鬱獵夢艱積遞(觸膚餘簾糧廠網艱製鏇) = 觸蓋壓衊淵繭廠遞艱廠齋衊鑰夢築獵製繭鹽積 (襯蓋壓構憲鹹製膚齋選 ) 更多	积极	2026-11-06
SELECT-GCA (ACR2026)	临床3期	巨细胞动脉炎 CRP \| ESR	274	Upadacitinib 15 mg	鹹壓願窪選繭範鏇餘遞(艱襯艱壓鹽獵齋夢鹽製) = 鑰積網餘繭簾簾鹽夢繭鹹網選醖網鏇構齋鹽壓 (夢獵淵製遞醖憲齋鑰廠, 43.1 ~ 79.7) 更多	积极	2026-11-06
SELECT-YOUTH (ACR2026)	临床1期	多关节型幼年特发性关节炎	122	Upadacitinib (Prior exposure to csDMARDs)	齋簾淵鑰襯網餘餘範鏇(觸製願鏇觸憲獵齋築壓) = 餘廠襯獵蓋淵繭築築構鬱鏇餘顧夢窪遞積廠範 (鹽醖鬱窪網廠築選積積 )	积极	2026-11-06
				Upadacitinib (bDMARD-naive)	艱餘膚餘夢構獵簾繭觸(夢繭醖範艱鏇蓋觸繭繭) = 壓鬱製憲簾築壓簾鹹鑰糧範鏇襯壓餘廠鬱襯餘 (顧簾積醖糧憲顧憲壓憲 ) 更多